As the mortality figures for COVID-19 continued to rise, people are wondering where they will stop. The actual death toll for COVID-19 will not be calculable for some time, but there are early indications that the mortality rate may be significantly lower than calculations of deaths per confirmed cases lead one to believe.
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
Incyte announced that data from the Phase 3 REACH2 study were published in The New England Journal of Medicine demonstrating that ruxolitinib – marketed in the United States as Jakafi – improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy.
Although not official and largely anecdotal, there are early signs that Gilead Sciences’ experimental antiviral drug remdesivir is effective in treating COVID-19.
Gilead Sciences Inc.’s shares surged 16 percent in after-hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
Sunovion Pharmaceuticals Inc. announced that results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of SEP-363856 in patients with schizophrenia were published online in the New England Journal of Medicine.
Gilead Sciences is running at least five clinical trials for the company’s experimental antiviral drug remdesivir against COVID-19.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints.
As the world shifts toward a concept of social distancing as part of an attempt to protect against the novel coronavirus, new research is showing the virus that causes COVID-19 is quite stable on hard surfaces, and even in the air.
The new anti-tuberculosis drug combination of bedaquiline, pretomanid and linezolid cures 90 percent of people with deadly drug-resistant TB if given for six months, researchers report in The New England Journal of Medicine.